Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
09 May 2022 - 10:30PM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), today announced that it will report financial results for
the first quarter ended March 31, 2022 on Monday, May 16, 2022,
before the open of U.S. markets. Following the announcement, the
Company will host a conference call and webcast at 8:30 a.m. ET to
provide a corporate update and review the financial results.
The conference call can be accessed by dialing
844-309-0618 (United States) or 661-378-9465 (International) with
the conference code 2495623. A live webcast may be accessed using
the link here, or by visiting the “Investors” section of the
Alaunos website at www.alaunos.com. After the live webcast, the
event will be archived on the Company’s website for approximately
30 days after the call.
About Alaunos
TherapeuticsAlaunos is a clinical-stage oncology-focused
cell therapy company, focused on developing T-cell receptor (TCR)
therapies based on its proprietary, non-viral Sleeping Beauty gene
transfer technology and its TCR library targeting shared
tumor-specific hotspot mutations in key oncogenic genes including
KRAS, TP53 and EGFR. The Company has clinical and strategic
collaborations with The University of Texas MD Anderson Cancer
Center and the National Cancer Institute. For more information,
please visit www.alaunos.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2024 to May 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From May 2023 to May 2024